| Literature DB >> 31807962 |
Weikun Meng1,2, Liang Gao1, Jagadeesh K Venkatesan1, Guanglin Wang2, Henning Madry1,3, Magali Cucchiarini4.
Abstract
BACKGROUND: Articular cartilage lesions generated by trauma or osteoarthritis are the most common causes of pain and disability in patients. The development of photopolymerizable hydrogels has allowed for significant advances in cartilage repair procedures. Such three-dimensional (3D) networks of polymers that carry large amounts of water can be created to resemble the physical characteristics of the articular cartilage and be delivered into ill-defined cartilage defects as a liquid solution prior to polymerization in vivo for perfect fit with the surrounding native tissue. These hydrogels offer an adapted environment to encapsulate and propagate regenerative cells in 3D cultures for cartilage repair. Among them, mesenchymal stem cells and chondrocytes may represent the most adapted sources for implantation. They also represent platforms to deliver therapeutic, biologically active factors that promote 3D cell differentiation and maintenance for in vivo repair.Entities:
Keywords: Articular cartilage; Biomolecules; Chondrocytes; Mesenchymal stem cells; Photopolymerizable hydrogels; Tissue engineering
Year: 2019 PMID: 31807962 PMCID: PMC6895316 DOI: 10.1186/s40634-019-0215-3
Source DB: PubMed Journal: J Exp Orthop ISSN: 2197-1153
Fig. 1Application of photopolymerizable hydrogel systems for translational cartilage repair. (a) Principle of providing a photopolymerizable hydrogel carrying cells (regenerative cells, chondrocytes) and/or specific growth factors or gene vectors as controlled delivery platforms to sites of articular cartilage damage (hydrogel gelation can be performed ex vivo or in situ following radiation with ultraviolet - UV - or visible light - VL). (b) Intra-operative administration of a photopolymerizable hydrogel accompanied with microfracture into a focal full-thickness chondral defect allowing for in situ gelation via UV light polymerization
Fig. 2Current literature available on the use of photopolymerizable hydrogels in cartilage repair research in vitro and in vivo. MSCs, mesenchymal stem cells; UV, ultraviolet; VL, visible light
Use of photopolymerizable hydrogels in vitro for applications in cartilage research
| Hydrogels | Factors | Photoinitiators | Cells | Follow-up | Results | References | |||
|---|---|---|---|---|---|---|---|---|---|
| Type | Wavelength (nm) | Time (min) | Intensity (mw/cm2) | ||||||
| PEODMa | – | UV | 365 | 10 | 10 | calf chondrocytes | 6 weeks | Maintained cell viability, uniform cell seeding, ECM is not compromised as the scaffold thickness is increased from 2 to 8 mm | (Bryant & Anseth, |
PEGDMa PEG-LA-DAb | – | UV | 365 | 20 | 10 | calf chondrocytes | 6 weeks | Chondrocytes encapsulated in hydrogels with at least 75% degradable crosslinks produced a cartilaginous tissue, increased type-II collagen synthesis | (Bryant & Anseth, |
| 10 | weeks | Production of similar biochemical matrix content to newly synthesized cartilaginous tissue, high compressive modulus to restore function and increase type-II collagen synthesis | (Buttgereit et al., | ||||||
| PEG/PEGDAa | – | UV | – | 4-10 | – | hBMSCs | 6 weeks | Greater PEGDA molecular weight did not affect proteoglycan content at a PEGDA:PEG ratio of 2:1 but did affect the distribution, addition of PEG to PEGDA hydrogels resulted in greater collagen content, facilitated cell chondrogenesis | (Buxton et al., |
| PEO/PEODMa | – | UV | – | 3 | 2-3 | bovine, ovine chondrocytes | 2 weeks | Chondrocyte survival and dispersed cell population composed of ovoid and elongated cells, proteoglycan and collagen contents increases over 2 weeks of static incubation, functional ECM with equilibrium moduli, dynamic stiffness, and streaming potentials that increased with time | (Elisseeff et al., |
MGC/MCSb MHA/MCSb | UV | 320–390 | 1 | 10 | bovine chondrocytes | 5 weeks | Improved cell viability and matrix production (aggrecan, type-II collagen), only MHA/MCS hydrogels retain an approximately constant modulus | (Hayami et al., | |
| Styrenated gelatina | – | VL | 400–520 | 2 | 800 | rabbit chondrocytes | 2 weeks | Maintained chondrogenic phenotype and cell viability | (Hoshikawa et al., |
Gel-MAb Gel-HAb Gel-CSb Gel-HA-CSb | – | UV | 365 | 15 | 2.6 | human chondrocytes | 8 weeks | Enhanced chondrogenesis and mechanical properties | (Levett et al., |
PEG-CAPa PEG-CAP-NORa | – | UV | 352 | 7 | – | bovine chondrocytes | 4 weeks | Increased sGAGs and collagen in the hydrogels with time, type-II collagen and aggrecan present in the neotissue with formation of a territorial matrix beginning at day 21, 8-fold increase in compressive modulus from days 7 to 28 | (Neumann et al., |
| PEODAa | – | UV | 365 | 7 | 3-4 | bovine chondrocytes | 7 weeks | MRI-derived measurements of matrix FCD in injectable hydrogels reflect tissue GAG content | (Ramaswamy et al., |
| PEG-LAb | – | UV | 365 | 10 | 6 | bovine chondrocytes | 4 weeks | Degradation led to 2.3- and 2.9-fold greater GAG and collagen contents compared with PEG group, respectively, macroscopic cartilage-like tissue formation (aggrecan, type-II and -VI collagen, link protein, and decorin) but decreased moduli, retention of the chondrocyte phenotype, proteoglycan and type-II collagen deposition | (Roberts et al., |
PEGDAa PEGTNB/PEGDSHa | – | UV | 352 | 10 | 6 | bovine chondrocytes | 2 weeks | PEGTNB led to hyaline-like cartilage production especially under mechanical loading, polymerization mechanism and network structure have long-term effects on the quality of engineered cartilage, especially under mechanical loading | (Roberts & Bryant, |
| MeGC/Colb | TGF-β1 | VL | 400–500 | 120 | 500–600 | hSMSCs | 3 weeks | TGF-β1 controlled release, maintained cell viability and chondrogenesis, cell aggregation and ECM deposition most particularly in the presence of TGF-β1 and type-II collagen impregnation relative to pure MeGC hydrogels | (Kim et al., |
| mGL/LAPa | TGF-β3 | VL | 430-490 | 2, 4, 8 | 1400 | hBMSCs | 13 weeks | High viability and chondrogenic differentiation of encapsulated cells | (Lin et al., |
| PEG/PEGDAa | TGF-β1 | UV | 365 | 5 | 4 | goat BMSCs | 6 weeks | Effective cell chondrogenesis, enhanced by TGF-β1 | (Williams et al., |
| PEODA/CMPb | CMP | UV | 365 | 5 | 5 | bovine chondrocytes | 2 weeks | Maintained cell viability, production of type-II collagen, CMP provides cell-manipulated crosslinks and collagen binding sites that simulate natural ECM | (Lee et al., |
aSynthetic photopolymerizable hydrogels; bnatural/synthetic (hybrid) photopolymerizable hydrogels. PEO poly (ethylene oxide), PEODM PEO-dimethacrylate, PEG poly (ethylene glycol), PEGDM PEG-dimethacrylate, PEG-LA-DA poly (lactic acid)-b-poly (ethylene glycol)-b-poly (lactic acid) endcapped with acrylate groups, PEGDA PEG-diacrylate, MGC N-methacrylate glycol chitosan, MCS O-methacrylate chondroitin sulfate, MHA O-methacrylate hyaluronic acid, Gel-MA gelatin-methacrylamide, Gel-HA gelatin-hyaluronic acid, Gel-CS gelatin-chondroitin sulfate, Gel-HA-CS gelatin-hyaluronic acid-chondroitin sulfate, PEG-CAP PEG-caprolactone, PEG-CAP-NOR PEG-CAP endcapped with norbornene, PEODA PEO-diacrylate, PEG-LA poly (lactic acid)-b-poly (ethylene glycol)-b-poly (lactic acid), PEGTNB PEG-tetranorbornene, PEGDSH PEG-dithiol, MeGC methacrylated chitosan, Col collagen, mGL methacrylated gelatin, LAP lithium phenyl-2,4,6-trimethylbenzoylphosphinate, CMP collagen mimetic peptide, TGF-β transforming growth factor beta, UV ultraviolet, VL visible light, MSCs mesenchymal stem cells, hBMSCs human bone marrow-derived MSCs, hSMSCs human synovium-derived MSCs, ECM extracellular matrix, sGAGs sulfated glycosaminoglycans, MRI magnetic resonance imaging, FCD fixed charge density
Use of photopolymerizable hydrogels in vivo for applications in cartilage research
| Hydrogels | Factors | Photoinitiators | Cells | Model | Follow-up | Results | References | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Wavelength (nm) | Time (min) | Intensity (mw/cm2) | |||||||
| PEODA/HAa,b | – | UV | – | 7 | 4–5 | hBMSCs | rabbit (full-thickness chondral defects) | 4 weeks | Cartilage repair after 28 days, enhanced cellularity of de novo tissues that filled the defects | (Dua et al., |
| MeHAb | – | UV | 360 | – | 1.2 | rat BMSCs | mice (full-thickness chondral defects) | 8 weeks | MeHA is biocompatible and osteoconductive, no sign of chondrocyte aggregation in the defects | (Lin et al., |
| mGL/MHAb | – | VL | 430–490 | 4 | 1400 | hBMSCs | rabbit (full-thickness osteochondral defects) | 12 weeks | MSC chondrogenesis, optimal cartilage and bone formation using mGL/MHA at 9:1 | (Lin et al., |
| PEG/MMP-2b | – | VL | 352 | 8 | 5 | rabbit BMSCs | rabbit (full-thickness osteochondral defects) | 24 weeks | MSC chondrogenesis in vivo | (Pascual-Garrido et al., |
| PEODA/HAb | – | UV | 365 | 5 | 6–8 | – | rabbit (full-thickness chondral defects) | 5 weeks | Cartilage repair | (Ramaswamy et al., |
| PEG/PCLa | – | VL | 450 | 1 | 1000 | human chondrocytes | rat (s.c.) | 4 weeks | ECM deposition (type-II and -VI collagen, GAGs), cartilage repair | (Werkmeister et al., |
| PEODA/HAb | TGF-β3 | UV | 365 | 10 | 4 | hBMSCs | mouse (s.c.) | 3 weeks | Chondrogenic differentiation | (Sharma et al., |
aSynthetic photopolymerizable hydrogels; bnatural/synthetic (hybrid) photopolymerizable hydrogels. PEODA poly (ethylene oxide) diacrylate, HA hyaluronic acid, MeHA or MHA methacrylated HA, mGL methacrylated gelatin, PEG poly (ethylene glycol), MMP-2 matrix metalloproteinase 2, PCL poly(ε-caprolactone), TGF-β transforming growth factor beta, UV ultraviolet, VL visible light, MSCs mesenchymal stem cells, hBMSCs human bone marrow-derived MSCs, s.c. subcutaneous, ECM extracellular matrix, GAGs glycosaminoglycans